Theranostics: A Unique Concept to Nuclear Medicine

Lucio Mango*

Published: 22 February, 2017 | Volume 1 - Issue 1 | Pages: 001-004

Nuclear Medicine is an integral part of modern healthcare. The use of radioactive nuclides tagged biomolecules, evaluating their distribution in human bodies by SPECT or PET systems, provides longitudinal sets of volumetric and quantitative images that can be used to diagnose a wide range of disease and/or assess response to disease specific treatments [1].

Read Full Article HTML DOI: 10.29328/journal.acst.1001001 Cite this Article Read Full Article PDF


  1. Hacker M, Beyer T, Baum RP, Kalemis A, Lammertsma AA, et al. Nuclear medicine innovations help (drive) healthcare (benefits). Eur J Nucl Med Mol Imaging. 2015; 42: 173-175. Ref.: https://goo.gl/vAgYqG
  2. Mango L, Pacilio M. Therapy with Alpha Rays. ARC Journal of Radiology and Medical Imaging. 2016; 1: 1-3.
  3. Pacilio M, Ventroni G, Basile C, Ialongo P, Becci D, et al. Improving the dose-myelotoxicity correlation in radiometabolic therapy of bone metastases with 153Sm-EDTMP. Eur J Nucl Med Mol Imaging. 2014; 41: 238-252. Ref.: https://goo.gl/I1OA8m
  4. Hamilton JG, Lawrence JH. Recent clinical developments in the therapeutic application of radio-phosphorus and radio-iodine. J Clin Invest. 1942; 21: 624. Ref.: http://bit.ly/2XIR7h8
  5. Lawrence JH. Nuclear physics and therapy. Preliminary report on a new method for the treatment of leukemia and polycythemia vera. Radiology. 1940; 35: 51-60. Ref.: http://bit.ly/2ZqDaEZ
  6. Hertz S, Roberts A. Radioactive iodine in the study of thyroid physiology; the use of radioactive iodine therapy in hyperthyroidism. J Am Med assoc. 1946; 131: 81-86. Ref.: https://goo.gl/mmYoKk
  7. Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res. 1974; 34: 1-9. Ref.: https://goo.gl/OmrVv1
  8. Goldenberg DM, DeLand F, Kim E, Bennett S, Primus FJ, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med. 1978; 298: 1384-1386 Ref.: https://goo.gl/Gk1VwV
  9. Das T, Pillai MR. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med and Biol. 2013; 40: 23-32. Ref.: https://goo.gl/EiuUuq
  10. Lee DY, Li KC. Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol. 2011; 197: 318-324. Ref.: https://goo.gl/0h8ZmI
  11. Pacilio M, Ventroni G, De Vincentis G, Cassano B, Pellegrini R, et al. Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting (223)Ra-dichloride. Eur J Nucl Med Mol Imaging. 2016; 43: 21-33. Ref.: https://goo.gl/HVOEZP
  12. Pacilio M, Ventroni G, Cassano B, Ialongo P, Lorenzon L, et al. A case report of image-based dosimetry of bone metastases with Alpharadin ( (223 Ra)-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up. Ann Nucl Med. 2016; 30: 163-168. Ref.: https://goo.gl/mcOeey
  13. Baidoo KE, Yong K, Brechbiel MW. Molecular pathways: targeted α-particle radiation therapy. Clin Cancer Res. 2013; 19: 530-537.Ref.: https://goo.gl/XSRSgu
  14. Wild D, Frischknecht M, Zhang H, Morgenstern A, Bruchertseifer F, et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN). Cancer Res. 2011; 71: 1009-1018. Ref.: https://goo.gl/zxLPpa
  15. Lewington VJ. Bone-Seeking Radionuclides for Therapy. J Nucl Med. 2005; 46: 38S-47S. Ref.: https://goo.gl/fBQ3R7
  16. Czernin J, Benz MR, Allen-Auerbach MS. PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010; 73: 470-480. Ref.: https://goo.gl/zabXUf
  17. Maecke HR, Reubi JC. Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment. J Nucl Med. 2011; 52: 841-844. Ref.: https://goo.gl/cz9aRd
  18. Velikyan I. Molecular imaging and radiotherapy: Theranostics for Personalized Patient Management. Theranostics. 2012; 2: 424-426. Ref.: https://goo.gl/vzwt6U
  19. Rösch F, and Baum RP. Generator-based PET radiopharmaceuticals for molecular imaging of tumours: on the way to THERANOSTICS. Dalton Trans. 2011; 40: 6104-6111. Ref.: https://goo.gl/1KqHaf
  20. Adams S, Baum RP, Hertel A, Wenish HJ, Staib-Sebler E, et al. Intraoperative Gamma Probe Detection of Neuroendocrine Tumors. J NucI Med. 1998; 99: 1155-1160. Ref.: https://goo.gl/0uCF8F
  21. Shi J , Liu TWB, Chen J, Green D, Jaffray D, et al. Transforming a Targeted Porphyrin Theranostic Agent into a PET Imaging Probe for Cancer. Theranostics. 2011; 1: 363-370. Ref.: https://goo.gl/Y9YP1L
  22. Del Vecchio S, Zannetti A, Fonti R, Pace L, Salvatore M. Nuclear imaging in cancer theranostics. Q J Nucl Med Mol Imaging. 2007; 5: 152-63. Ref.: https://goo.gl/3wMB7R
  23. Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989; 1: 242-244. Ref.: https://goo.gl/COL0hA

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?